HOME > TOP STORIES
TOP STORIES
-
REGULATORY Japan Pharmaceutical Association Vice President Hirotsugu Miura Says that 70% Rule for New Generics Will Be Debatable in Future
March 15, 2013
-
BUSINESS Sanofi Japan Aims to Enhance Leadership Status in Diabetes Sector with GLP-1, President Says
March 14, 2013
-
BUSINESS Biosimilar Makers Getting Premium-Linked Inquiries from Medical Institutions
March 13, 2013
-
BUSINESS Overseas Business Making Up for Sluggish Domestic Market; Weaker Yen Could Add Further Boost in 4th Quarter
March 13, 2013
-
BUSINESS Wholesalers’ Price Negotiations Likely to Be Carried Over to New Fiscal Year; Unsettlement Rates Could Hit Double-Digit Figures
March 12, 2013
-
BUSINESS Otsuka, Lundbeck to Expand Collaboration, Copromote Abilify in US, Europe
March 11, 2013
-
BUSINESS Sandoz Will See Accelerated Growth of Japan Operations in 2013: Global Head
March 11, 2013
-
BUSINESS Eisai to Reorganize Sales Force in Japan to Secure Aricept Market Share
March 8, 2013
-
ORGANIZATION Japan Society of Generic Medicines Calls for 80% Generic Drug Share by Volume within 5 Years
March 8, 2013
-
BUSINESS Ajinomoto to Acquire US Contract Biologic Manufacturer Althea
March 7, 2013
-
REGULATORY MHLW Approves 45 New Compounds in 2012: Mr Akagawa of PFSB
March 6, 2013
-
BUSINESS 2 SGLT-2 Inhibitors to Be Filed for Approval without Concurrent-Use Restrictions
March 5, 2013
-
BUSINESS Pfizer Positive about In-Licensing Other Firms’ Long-Listed Drugs: VP Matsumori
March 5, 2013
-
REGULATORY Lawmakers Organizing Non-Partisan Group to Break Deadlock on Establishment of 3rd-Party Drug Administration Watchdog Organization
March 5, 2013
-
BUSINESS Pfizer Japan’s Ethical Drug Sales Dip 4.2% on Lipitor Patent Expiry: FY2012 Earnings
March 4, 2013
-
BUSINESS ARB Sales Apparently Peak Out in Japan Antihypertensive Market
March 1, 2013
-
REGULATORY 5 Years Too Long to Achieve Reference Generic Share Target of 60%: Bill Payer Reps at CSIMC Subcommittee
February 28, 2013
-
ORGANIZATION Relationships with Doctors Unchanged after Stricter Rules on Entertainment: Maker FTC Survey
February 27, 2013
-
REGULATORY JMACCT Revamps Database of Clinical Trial Institutions; Details Now Available Online
February 27, 2013
-
BUSINESS Takeda Recalling Renal Anemia Drug Omontys in US after Death Reports
February 26, 2013
ページ
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…